TOKYO and ROME, November 21,
2017 /PRNewswire/ --
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; hereinafter "Sumitomo Dainippon
Pharma") and Angelini S.p.A. (Head Office: Rome, Italy; CEO: Gianluigi Frozzi; hereinafter "Angelini")
announced today that the companies have formed a partnership
(entering into a license and distribution agreement) with the goal
to expand availability in Europe
of Latuda® (generic name: lurasidone hydrochloride;
hereinafter "LATUDA"), an atypical antipsychotic which was created
by Sumitomo Dainippon Pharma.
(Logo:
http://mma.prnewswire.com/media/608004/Sumitomo_Dainippon_Pharma_and_Angelini_Logo.jpg
)
Under the terms of the agreement, Sunovion Pharmaceuticals
Europe Ltd., a subsidiary company of Sumitomo Dainippon Pharma
Group, (hereinafter "Sunovion Europe") has granted Angelini
exclusive commercialization rights for LATUDA in 29 European
countries[*] and in Turkey (hereinafter "Territory").
Sunovion Europe is transferring the marketing authorization for
LATUDA in Europe to Angelini.
Furthermore, Sumitomo Dainippon Pharma will supply LATUDA bulk
tablets, or final products to Angelini.
Angelini will hold the marketing authorization for LATUDA in
Europe and will commercialize it
in the Territory. Angelini will begin to distribute LATUDA in
Italy to mark the first country in
the Territory, by the end of 2017. Sunovion Europe will continue to
distribute LATUDA in the United
Kingdom, Switzerland,
Norway, Finland, Sweden, Denmark and the
Netherlands, where it has already been launched.
"Sumitomo Dainippon Pharma has been seeking to establish a
partnership for commercialization of LATUDA in Europe after a partnership on LATUDA business
in Europe with Takeda
Pharmaceutical Company Limited was terminated in 2015. We are
pleased to announce the partnership with Angelini," said
Masayo Tada, Representative
Director, President and CEO of Sumitomo Dainippon Pharma. "We
expect to provide this therapeutic option to a greater number of
patients in Europe."
"Central nervous system (CNS) diseases and disorders are one of
our focus therapeutic areas, and we are pleased to enhance our
already strong product portfolio by introducing LATUDA," said
Gianluigi Frozzi, CEO of Angelini. "We will work closely with
Sunovion Europe to make LATUDA available in a greater number of
European countries."
* Italy, San Marino, Vatican
City, Spain, Andorra, Austria, Bulgaria, Croatia, Cyprus, Czechia, Greece, Hungary, Poland, Portugal, Romania, Slovenia, Slovakia, Russia, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Ukraine, Tajikistan, Turkmenistan, Uzbekistan
(References)
About Latuda[®]
LATUDA is an atypical antipsychotic created originally by
Sumitomo Dainippon Pharma, characterized by a unique chemical
structure and an affinity for dopamine D2, serotonin
5-HT2A and serotonin 5-HT7 receptors where it
has antagonist effects. In addition, LATUDA is a partial agonist at
the serotonin 5-HT1A receptor and has no appreciable
affinity for histamine H1 or muscarinic M1
receptors.
LATUDA has been available for the treatment of schizophrenia in
the United States since 2011, in
Canada since 2012, in Switzerland since 2013, in Denmark, Norway and the U.K. since 2014, in
the Netherlands, Finland and Australia since 2015, in Sweden since 2016, and in Thailand, Hong
Kong and Singapore since
2017. Sumitomo Dainippon Pharma is conducting Phase 3 studies with
a view to obtaining approvals of LATUDA for the treatment of
schizophrenia, bipolar I depression and bipolar maintenance in
Japan and submitted the New Drug
Application for the treatment of schizophrenia in China. Similar efforts are ongoing in
collaboration with Daiichi Sankyo Company, Limited for four Latin
American countries, with Standard Chem. & Pharm. Co., Ltd. for
Taiwan, with DKSH (Thailand) Limited for Thailand, Singapore and Hong
Kong, with Bukwang Pharmaceutical Co., Ltd. for Korea, with
Servier Laboratories Australia Pty Ltd. for Australia and with NewBridge Pharmaceuticals
Limited for the six countries of the Gulf Cooperation Council
including Saudi Arabia and
Kuwait.
About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd., defines its corporate
mission as "to broadly contribute to society through value creation
based on innovative research and development activities for the
betterment of healthcare and fuller lives for people worldwide". By
pouring all our efforts into the research and development of new
drugs, we aim to provide innovative and effective pharmaceutical
solutions to people not only in Japan but also around the world in order to
realize our corporate mission. For more details, please visit
Sumitomo Dainippon Pharma's website (http://www.ds-pharma.com/
).
About Angelini Group
Angelini is a privately owned international group. Founded in
Italy in the early 20th century,
it has branches in 20 countries and employs approximately 6,000
people. The pharmaceutical sector is the core business,
representing over 50% of the Angelini group, €1.6 billion 2016
revenue.
Angelini pharmaceutical products are available in over 60
countries through its branches and an extensive network of
licensees and strategic agreements with local pharmaceutical
companies.
The company portfolio focuses mainly on pain relief,
inflammation, CNS, anti-infectives, gynecology and has a strong
position in the OTC market. The R&D department is currently
working on several projects in the areas of Pain & Inflammation
Disorders, Infection Control & Infectious Diseases and Nervous
System Diseases & Disorders. In the latter, R&D is active
with discovery programs, including private-public projects with New
Chemical Entities, as well as clinical studies (phase I and II) and
with clinical studies for already marketed products fully developed
by Angelini. For more details, please visit Angelini's website
(http://www.angelinipharma.com ).
SOURCE Sumitomo Dainippon Pharma Co., Ltd and Angelini